Summary by Moomoo AI
BeiGene achieved $1 billion in quarterly revenue, with product sales reaching $993 million, up 67% YoY. BRUKINSA led growth with U.S. sales of $504 million (+87% YoY) and European sales of $97 million (+217% YoY). The company reported reduced GAAP operating loss of $120 million and second consecutive quarter of positive non-GAAP operating income at $66 million.The company strengthened its hematology franchise leadership with BRUKINSA showing strong momentum in CLL treatment. Key pipeline developments include continued enrollment in global Phase 3 trials for sonrotoclax and advancement of BTK degrader BGB-16673. Four new molecular entities entered clinical trials this quarter, bringing the year-to-date total to eight, with more planned for Q4.BeiGene's operational efficiency improved with cash flow from operations reaching $188 million, a $267 million increase YoY. The company maintains a strong balance sheet with $2.7 billion in cash and equivalents. Research and development expenses increased 9% YoY to $496 million, while SG&A expenses as a percentage of product sales improved to 46% from 61% in the prior year.
